Question explored with the scientific record
Do ivermectin cases where patients recovered prove the drug caused the recovery?
The short version: a patient recovering after taking ivermectin does not prove the drug caused the recovery.
Most people with mild COVID-19 recover on their own. That is the baseline. A retrospective study of 338 patients treated at home with ivermectin plus supplements reported 95.6% recovered [1], but it had no comparator group, so we cannot know how many would have recovered without the drug. The authors themselves caution against generalizing [1].
The controlled evidence points the other way. A 2026 meta-analysis of 40 randomized trials with 23,243 participants found no significant effect of ivermectin on infection rate, mortality, or most outcomes [2]. A 2022 randomized trial in severe COVID-19 found no significant difference in ICU admission, ventilation, or death versus placebo [3]. A 2025 meta-analysis of 23 trials found no significant improvement in viral clearance, hospitalization duration, or symptom resolution [6].
| Outcome | Ivermectin | Control | Significant? |
|---|---|---|---|
| Mortality (hospitalized) | RR 0.94 | baseline | No [2] |
| Mortality (outpatient) | RR 0.88 | baseline | No [2] |
| ICU admission (severe) | 21.6% | 15.8% | No [3] |
| Symptom resolution (mild) | 82% by day 21 | 79% | No [4] |
The observational studies that look positive are exactly the ones that cannot prove causation. They lack control groups, compare treated to untreated people who differed in other ways, or compare against regional averages [1][5][7]. A recovery story is a data point, not evidence.
My call: individual recoveries after ivermectin do not prove the drug caused them. The randomized evidence shows no meaningful benefit. Confidence: high.
Sources used 7
-
The Use of Oral Human Grade Ivermectin with Supplements Known as Immunomodulators for Treating Patients with COVID-19 Infections at Home
An ex post facto study of 338 COVID-19 patients treated at home with oral ivermectin plus immunomodulator supplements in Metro Manila reported 95.6% complete recovery and found that gender, comorbidity, shortness of breath, muscle pain, headache, combination immunomodulators, an…
DOI: 10.46889/jcim.2022.3205 -
The role of ivermectin in the prevention and treatment of SARS-CoV-2 infection: a meta-analysis of randomized controlled trials
In 40 RCTs (23,243 participants), ivermectin showed no statistically significant preventive or therapeutic benefit for SARS-CoV-2 infection, with no significant effects on infection rate, mortality, adverse events, or most secondary outcomes.
DOI: 10.1186/s12879-026-13195-9 -
Clinical efficacy and safety of ivermectin (400 ug/kg, single dose) in patients with severe COVID-19: a randomized clinical trial
Among hospitalized adults with severe COVID-19, adding a single 400 μg/kg dose of ivermectin to standard care, compared with placebo, produced no significant difference in 21-day ICU admission, invasive mechanical ventilation, mortality, or adverse events.
DOI: 10.22354/24223794.1105 -
Covid-19: Effects of Azithromycin/Hydroxychloroquine/Ivermectin in ambulatory and hospitalized patients
This systematic review of 17 studies found limited, low-quality evidence that azithromycin, hydroxychloroquine, and ivermectin provide no clinical benefit in COVID-19 outpatients or inpatients.
DOI: 10.54034/mic.e1231 -
Early Outpatient Treatment of COVID-19: A Retrospective Analysis of 392 Cases in Italy
Early outpatient treatment of COVID-19 with combined anti-inflammatory, antiplatelet, and anticoagulant drugs was associated with low hospitalization (5.8%) and mortality (0.2%) rates in a retrospective cohort of 392 Italian patients treated within the IppocrateOrg network.
DOI: 10.3390/jcm11206138 -
Repurposing Anthelmintic Drugs for COVID-19 Treatment: A Comprehensive Meta-Analysis of Randomized Clinical Trials on Ivermectin and Mebendazole
An up-to-date meta-analysis of 23 randomized trials (n = 12,345) evaluating ivermectin and mebendazole for COVID-19 found no statistically significant improvement in viral clearance, hospitalization duration, or symptom resolution overall, although some individual studies sugges…
DOI: 10.3390/antibiotics14050459 -
Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection
In a retrospective series of 320 high-risk outpatients with suspected or confirmed COVID-19 treated with empiric multidrug therapy, hospitalization occurred in 6 (1.9%) and death in 1 (0.3%), suggesting low event rates but lacking a control group.
DOI: 10.31083/j.rcm.2020.04.260